Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
出版年份 2017 全文链接
标题
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 20, Issue 10, Pages 788-796
出版商
Oxford University Press (OUP)
发表日期
2017-05-17
DOI
10.1093/ijnp/pyx038
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanism of action of cariprazine
- (2016) Stephen M. Stahl CNS SPECTRUMS
- Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
- (2016) Jo C. Neill et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
- (2016) David J.G. Watson et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO
- (2016) Ragy R. Girgis et al. PSYCHOPHARMACOLOGY
- P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial
- (2015) M. Debelle et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial
- (2015) Gary S. Sachs et al. JOURNAL OF AFFECTIVE DISORDERS
- The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial
- (2014) Suresh Durgam et al. BIPOLAR DISORDERS
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
- (2014) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- Long-term effects of cariprazine exposure on dopamine receptor subtypes
- (2013) Yong Kee Choi et al. CNS SPECTRUMS
- Cariprazine, a new, orally active dopamine D2/3receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression
- (2013) Tanja Veselinović et al. Expert Review of Neurotherapeutics
- Antidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression
- (2012) Maha Elsayed et al. BIOLOGICAL PSYCHIATRY
- Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors
- (2012) Éva Ágai-Csongor et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes
- (2012) Vanja Duric et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse
- (2012) Ross Zimnisky et al. PSYCHOPHARMACOLOGY
- Poster #16 CARIPRAZINE, A D3/D2 DOPAMINE RECEPTOR PARTIAL AGONIST ANTIPSYCHOTIC, DISPLAYS GREATER D3 RECEPTOR OCCUPANCY IN VIVO COMPARED WITH OTHER ANTIPSYCHOTICS
- (2012) Bela Kiss et al. SCHIZOPHRENIA RESEARCH
- In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors
- (2011) Yoshihiro Tadori et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
- (2011) István Gyertyán et al. NEUROCHEMISTRY INTERNATIONAL
- Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO
- (2011) Romina Mizrahi et al. SCHIZOPHRENIA RESEARCH
- Antipsychotic-Induced Hyponatraemia
- (2010) Didier Meulendijks et al. DRUG SAFETY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A negative regulator of MAP kinase causes depressive behavior
- (2010) Vanja Duric et al. NATURE MEDICINE
- Nuclear factor- B is a critical mediator of stress-impaired neurogenesis and depressive behavior
- (2010) J. W. Koo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
- (2009) J. Craig Nelson et al. AMERICAN JOURNAL OF PSYCHIATRY
- Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor
- (2009) Alex V. Yarkov et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice
- (2009) Michel Bourin et al. PSYCHOPHARMACOLOGY
- The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study
- (2008) Ariel Graff-Guerrero et al. NEUROPSYCHOPHARMACOLOGY
- Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour
- (2008) S CHOURBAJI et al. PHARMACOLOGICAL RESEARCH
- IL-1 is an essential mediator of the antineurogenic and anhedonic effects of stress
- (2008) J. W. Koo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST)
- (2007) Gian Marco Leggio et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started